Is Syncom Formul. overvalued or undervalued?

As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. The PE ratio stands at 24.77, while the EV to EBITDA ratio is 21.23, and the PEG ratio is notably low at 0.28, indicating that the stock may not be justified at its current price given its growth prospects.
In comparison to its peers, Syncom Formul. has a higher PE ratio than Cipla, which is attractive at 22.72, and significantly higher than Dr. Reddy's Labs, which has a PE of 18. Additionally, the company's EV to EBITDA ratio is also above the industry average, further supporting the overvaluation stance. While the stock has performed well over the long term, with a 5-year return of 802.17%, recent performance has lagged behind the Sensex, with a year-to-date decline of 17.00% compared to the Sensex's gain of 8.22%.